We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

Gastroenterology

5

GELSECTAN® launched in Portugal

We are glad to announce the launch of GELSECTAN® in its second market, Portugal, by our partner Norgine. Product presentations were given to the Portuguese Gastrointestinal community in Lisbon, Oporto, and Coimbra. The GELSECTAN® mode of action, based on its innovative barrier technology, raised great interest among gastroenterologists who treat IBS-D patients.

Read more

New scientific publication on Mucoprotection and diarrheal processes.

Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6

Clarifying the role of intestinal mucus in reducing inflammation and infection has led to the development of ‘mucosal protectors’. These agents form a bioprotective film in the gastrointestinal tract and potentially may prevent microorganisms from crossing the mucus barrier. To date, the most widely studied substances include xyloglucan (Xilaplus®) and gelatin tannate (Tasectan®, Gelenterum®). 2 new clinical studies are about to start to increase the body of evidence of those substances. Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6

Read more

Let's meet in..

2019, Nov 05

CPhI 2019

Read more

2019, Nov 25

euroPLX 71

Read more

2019, Nov 28

PharmaVenue November 2019

Read more